摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Acetyl-4-(triazol-2-yl)benzamide

中文名称
——
中文别名
——
英文名称
3-Acetyl-4-(triazol-2-yl)benzamide
英文别名
3-acetyl-4-(triazol-2-yl)benzamide
3-Acetyl-4-(triazol-2-yl)benzamide化学式
CAS
——
化学式
C11H10N4O2
mdl
——
分子量
230.22
InChiKey
UKEYFZRVKITQLE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    90.9
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • [EN] 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES 2-PYRIDYLOXY-4-ÉTHER DES RÉCEPTEURS DE L'OREXINE
    申请人:MERCK SHARP & DOHME
    公开号:WO2014137883A1
    公开(公告)日:2014-09-12
    The present invention is directed to 2-pyridyloxy-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved..
    本发明涉及2-吡啶氧基-4-醚化合物,这些化合物是促进睡眠的受体拮抗剂。本发明还涉及在潜在治疗或预防神经系统和精神疾病中使用本文所述的2-吡啶氧基-4-醚化合物。本发明还涉及包括这些化合物的药物组合物。本发明还涉及在预防或治疗涉及促进睡眠的受体的这些疾病中使用这些药物组合物。
  • [EN] THIOETHER-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS THIOÉTHER-PIPÉRIDINYLE SERVANT D'ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
    申请人:MERCK SHARP & DOHME
    公开号:WO2015095108A1
    公开(公告)日:2015-06-25
    The present invention is directed to thioether-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thioether-piperidinyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及硫醚哌啶基化合物,其为俄雷欣受体拮抗剂。本发明还涉及所述硫醚哌啶基化合物在潜在治疗或预防神经学和精神疾病中的用途,其中俄雷欣受体参与其中。本发明还涉及包含这些化合物的药物组合物。本发明还涉及这些药物组合物在预防或治疗俄雷欣受体参与的疾病中的用途。
  • 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS
    申请人:KUDUK Scott D.
    公开号:US20160016935A1
    公开(公告)日:2016-01-21
    The present invention is directed to 2-pyridyloxy-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及2-吡啶氧基-4-醚类化合物,其为促进睡眠荷尔蒙受体的拮抗剂。本发明还涉及使用此处所述的2-吡啶氧基-4-醚类化合物在潜在的神经和精神障碍和疾病的治疗或预防中,其中促进睡眠荷尔蒙受体发挥作用。本发明还涉及包含这些化合物的药物组合物。本发明还涉及使用这些药物组合物在预防或治疗促进睡眠荷尔蒙受体发挥作用的疾病中。
  • THIOETHER-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS
    申请人:MERCK SHARP & DOHME CORP.
    公开号:US20160318899A1
    公开(公告)日:2016-11-03
    The present invention is directed to thioether-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thioether-piperidinyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
  • US9617246B2
    申请人:——
    公开号:US9617246B2
    公开(公告)日:2017-04-11
查看更多